To Evaluate the Safety, Tolerability and Pharmacokinetics of CT-P59 in Healthy Subjects

NCT04525079 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

32

Enrollment

INDUSTRY

Sponsor class

Conditions

SARS-CoV-2 Infection

Interventions

DRUG: CT-P59
DRUG: Placebo

Sponsor

Celltrion